Cara Therapeutics, Inc. (NASDAQ:CARA) VP Frederique Ph.D. Menzaghi sold 3,000 shares of the company’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $15.00, for a total value of $45,000.00. Following the sale, the vice president now owns 120,000 shares in the company, valued at approximately $1,800,000. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Cara Therapeutics, Inc. (NASDAQ:CARA) traded down 1.81% on Tuesday, reaching $15.15. The company had a trading volume of 1,683,716 shares. The stock has a 50 day moving average of $18.44 and a 200 day moving average of $15.55. The firm’s market capitalization is $492.48 million. Cara Therapeutics, Inc. has a 12 month low of $4.75 and a 12 month high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by $0.08. The company had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $0.11 million. The firm’s revenue was up 12900.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.39) earnings per share. On average, analysts anticipate that Cara Therapeutics, Inc. will post ($2.44) EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/07/18/frederique-ph-d-menzaghi-sells-3000-shares-of-cara-therapeutics-inc-cara-stock.html.

Several brokerages have weighed in on CARA. Canaccord Genuity set a $25.00 price target on Cara Therapeutics and gave the stock a “buy” rating in a report on Saturday, July 1st. Piper Jaffray Companies restated a “buy” rating and set a $27.00 price target on shares of Cara Therapeutics in a report on Saturday, July 1st. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Cara Therapeutics in a report on Monday, April 24th. Royal Bank Of Canada dropped their price objective on Cara Therapeutics from $32.00 to $31.00 and set an “outperform” rating on the stock in a report on Monday, May 15th. Finally, Vetr downgraded Cara Therapeutics from a “strong-buy” rating to a “buy” rating and set a $21.73 price objective on the stock. in a report on Wednesday, June 21st. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $25.68.

Hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in shares of Cara Therapeutics during the first quarter valued at $124,000. UBS Group AG raised its stake in shares of Cara Therapeutics by 16.9% in the first quarter. UBS Group AG now owns 10,544 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,528 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of Cara Therapeutics by 0.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 11,824 shares of the biopharmaceutical company’s stock valued at $217,000 after buying an additional 60 shares in the last quarter. American International Group Inc. raised its stake in shares of Cara Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,937 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 857 shares in the last quarter. Finally, Two Sigma Securities LLC purchased a new stake in shares of Cara Therapeutics during the first quarter valued at $252,000. 52.91% of the stock is owned by hedge funds and other institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.